CN104804079A - 伊马替尼免疫原、衍生物及合成方法、特异性抗体和检测试剂及制备方法 - Google Patents
伊马替尼免疫原、衍生物及合成方法、特异性抗体和检测试剂及制备方法 Download PDFInfo
- Publication number
- CN104804079A CN104804079A CN201510235969.1A CN201510235969A CN104804079A CN 104804079 A CN104804079 A CN 104804079A CN 201510235969 A CN201510235969 A CN 201510235969A CN 104804079 A CN104804079 A CN 104804079A
- Authority
- CN
- China
- Prior art keywords
- imatinib
- derivative
- solution
- antibody
- specific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005517 L01XE01 - Imatinib Substances 0.000 title claims abstract description 119
- 229960002411 imatinib Drugs 0.000 title claims abstract description 118
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title claims abstract description 115
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 47
- 230000002163 immunogen Effects 0.000 title claims abstract description 37
- 238000001514 detection method Methods 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 238000001308 synthesis method Methods 0.000 title abstract 2
- 239000000243 solution Substances 0.000 claims description 45
- 102000004190 Enzymes Human genes 0.000 claims description 44
- 108090000790 Enzymes Proteins 0.000 claims description 44
- 150000004926 Imatinib derivatives Chemical class 0.000 claims description 41
- 102100031126 6-phosphogluconolactonase Human genes 0.000 claims description 30
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims description 30
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims description 30
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 239000000758 substrate Substances 0.000 claims description 19
- 238000003786 synthesis reaction Methods 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000007983 Tris buffer Substances 0.000 claims description 15
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 238000010171 animal model Methods 0.000 claims description 12
- 238000013016 damping Methods 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 230000000890 antigenic effect Effects 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 8
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 7
- 230000021615 conjugation Effects 0.000 claims description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- KYLVAMSNNZMHSX-UHFFFAOYSA-N methyl 6-bromohexanoate Chemical class COC(=O)CCCCCBr KYLVAMSNNZMHSX-UHFFFAOYSA-N 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical class CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 claims description 4
- 108010017384 Blood Proteins Proteins 0.000 claims description 4
- 102000004506 Blood Proteins Human genes 0.000 claims description 4
- 102000014914 Carrier Proteins Human genes 0.000 claims description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 229940125898 compound 5 Drugs 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine group Chemical class C(CCC)N(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 claims description 4
- CCMKPCBRNXKTKV-UHFFFAOYSA-N 1-hydroxy-5-sulfanylidenepyrrolidin-2-one Chemical compound ON1C(=O)CCC1=S CCMKPCBRNXKTKV-UHFFFAOYSA-N 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 3
- 108010034949 Thyroglobulin Proteins 0.000 claims description 3
- 102000009843 Thyroglobulin Human genes 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000005227 gel permeation chromatography Methods 0.000 claims description 3
- 108060003552 hemocyanin Proteins 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 239000008057 potassium phosphate buffer Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000012264 purified product Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 229960002175 thyroglobulin Drugs 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000012460 protein solution Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 230000000392 somatic effect Effects 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 11
- 230000005847 immunogenicity Effects 0.000 abstract description 8
- 230000035945 sensitivity Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000523 sample Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 10
- 238000003018 immunoassay Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000011084 recovery Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000006837 decompression Effects 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000143437 Aciculosporium take Species 0.000 description 2
- 241001131796 Botaurus stellaris Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000013062 quality control Sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- FAHUKNBUIVOJJR-UHFFFAOYSA-N 1-(4-fluorophenyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1C1C2=CC=CN2CCN1 FAHUKNBUIVOJJR-UHFFFAOYSA-N 0.000 description 1
- YUUHHSMHLNDBCB-UHFFFAOYSA-N 1-(5-amino-2-methylphenyl)-4-pyridin-3-yl-2h-pyrimidin-2-amine Chemical compound CC1=CC=C(N)C=C1N1C(N)N=C(C=2C=NC=CC=2)C=C1 YUUHHSMHLNDBCB-UHFFFAOYSA-N 0.000 description 1
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000004860 Blast Crisis Diseases 0.000 description 1
- JGOFKAHLQQITIG-UHFFFAOYSA-N CC(C)(C)OC(N1CCN(Cc(cc2)ccc2C(O)=O)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(Cc(cc2)ccc2C(O)=O)CC1)=O JGOFKAHLQQITIG-UHFFFAOYSA-N 0.000 description 1
- FVMXNXMOUWFRMQ-UHFFFAOYSA-N CC(C)(C)OC(N1CCN(Cc(cc2)ccc2C(OC)=O)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(Cc(cc2)ccc2C(OC)=O)CC1)=O FVMXNXMOUWFRMQ-UHFFFAOYSA-N 0.000 description 1
- 0 Cc(c(Nc1nc(-c2cccnc2)ccn1)c1)ccc1NC(c1ccc(CN2CCN(C*)CC2)cc1)=O Chemical compound Cc(c(Nc1nc(-c2cccnc2)ccn1)c1)ccc1NC(c1ccc(CN2CCN(C*)CC2)cc1)=O 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- -1 contains HPLC-UV Chemical compound 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- QAWFLJGZSZIZHO-UHFFFAOYSA-N methyl 4-bromobutanoate Chemical compound COC(=O)CCCBr QAWFLJGZSZIZHO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
血液样品 | 低 | 中 | 高 |
样品浓度(ng/ml) | 50.00 | 300.00 | 800.00 |
1 | 50.83 | 304.46 | 815.26 |
2 | 51.01 | 293.33 | 809.41 |
3 | 50.00 | 305.51 | 789.98 |
4 | 52.09 | 301.80 | 805.33 |
5 | 51.08 | 304.69 | 812.95 |
6 | 50.25 | 310.47 | 793.11 |
7 | 48.04 | 295.52 | 808.50 |
8 | 49.19 | 301.60 | 800.33 |
9 | 52.50 | 300.52 | 795.90 |
10 | 49.93 | 307.75 | 814.92 |
平均值(ng/ml) | 50.49 | 302.57 | 804.57 |
标准差(SD) | 1.3182 | 5.2363 | 9.2401 |
精密度(CV%) | 2.61 | 1.73 | 1.15 |
回收率% | 101.0 | 100.9 | 100.6 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510235969.1A CN104804079B (zh) | 2015-05-11 | 2015-05-11 | 伊马替尼免疫原、衍生物及合成方法、特异性抗体和检测试剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510235969.1A CN104804079B (zh) | 2015-05-11 | 2015-05-11 | 伊马替尼免疫原、衍生物及合成方法、特异性抗体和检测试剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104804079A true CN104804079A (zh) | 2015-07-29 |
CN104804079B CN104804079B (zh) | 2018-07-13 |
Family
ID=53689303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510235969.1A Active CN104804079B (zh) | 2015-05-11 | 2015-05-11 | 伊马替尼免疫原、衍生物及合成方法、特异性抗体和检测试剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104804079B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105175531A (zh) * | 2015-08-14 | 2015-12-23 | 苏州博源医疗科技有限公司 | 羟脯氨酸免疫原、特异性抗体、检测试剂及其制备方法 |
IT201900008808A1 (it) | 2019-06-13 | 2020-12-13 | Univ Ca Foscari | Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma |
CN112920163A (zh) * | 2021-01-26 | 2021-06-08 | 华中科技大学同济医学院附属协和医院 | 一种伊马替尼和n-去甲基伊马替尼的半抗原、抗原和抗体以及其应用 |
CN112924668A (zh) * | 2021-01-26 | 2021-06-08 | 北京丹大生物技术有限公司 | 一种伊马替尼和/或n-去甲基伊马替尼的免疫学检测方法 |
CN112946282A (zh) * | 2021-01-26 | 2021-06-11 | 北京丹大生物技术有限公司 | 一种用于检测伊马替尼和/或n-去甲基伊马替尼的检测试剂和检测试剂盒 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102625702A (zh) * | 2009-08-19 | 2012-08-01 | 萨拉戴克斯生物医学公司 | 伊马替尼免疫测定法 |
CN103804491A (zh) * | 2014-02-11 | 2014-05-21 | 苏州博源医疗科技有限公司 | 1,5-脱水山梨醇免疫原及其特异性抗体及检测试剂 |
CN104483407A (zh) * | 2014-12-18 | 2015-04-01 | 首都医科大学附属北京世纪坛医院 | 血样中微量伊马替尼测定方法及在零期临床试验中的应用 |
CN104530222A (zh) * | 2014-12-20 | 2015-04-22 | 苏州博源医疗科技有限公司 | 紫杉醇免疫原、抗紫杉醇特异性抗体和紫杉醇检测试剂 |
-
2015
- 2015-05-11 CN CN201510235969.1A patent/CN104804079B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102625702A (zh) * | 2009-08-19 | 2012-08-01 | 萨拉戴克斯生物医学公司 | 伊马替尼免疫测定法 |
CN103804491A (zh) * | 2014-02-11 | 2014-05-21 | 苏州博源医疗科技有限公司 | 1,5-脱水山梨醇免疫原及其特异性抗体及检测试剂 |
CN104483407A (zh) * | 2014-12-18 | 2015-04-01 | 首都医科大学附属北京世纪坛医院 | 血样中微量伊马替尼测定方法及在零期临床试验中的应用 |
CN104530222A (zh) * | 2014-12-20 | 2015-04-22 | 苏州博源医疗科技有限公司 | 紫杉醇免疫原、抗紫杉醇特异性抗体和紫杉醇检测试剂 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105175531A (zh) * | 2015-08-14 | 2015-12-23 | 苏州博源医疗科技有限公司 | 羟脯氨酸免疫原、特异性抗体、检测试剂及其制备方法 |
IT201900008808A1 (it) | 2019-06-13 | 2020-12-13 | Univ Ca Foscari | Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma |
CN112920163A (zh) * | 2021-01-26 | 2021-06-08 | 华中科技大学同济医学院附属协和医院 | 一种伊马替尼和n-去甲基伊马替尼的半抗原、抗原和抗体以及其应用 |
CN112924668A (zh) * | 2021-01-26 | 2021-06-08 | 北京丹大生物技术有限公司 | 一种伊马替尼和/或n-去甲基伊马替尼的免疫学检测方法 |
CN112946282A (zh) * | 2021-01-26 | 2021-06-11 | 北京丹大生物技术有限公司 | 一种用于检测伊马替尼和/或n-去甲基伊马替尼的检测试剂和检测试剂盒 |
CN112946282B (zh) * | 2021-01-26 | 2022-08-09 | 北京丹大生物技术有限公司 | 一种用于检测伊马替尼和/或n-去甲基伊马替尼的检测试剂和检测试剂盒 |
CN112920163B (zh) * | 2021-01-26 | 2023-09-26 | 华中科技大学同济医学院附属协和医院 | 一种伊马替尼和n-去甲基伊马替尼的半抗原、抗原和抗体以及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104804079B (zh) | 2018-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103760348B (zh) | 一种甘胆酸免疫检测试剂及其制备和检测方法 | |
CN102768284B (zh) | 一种卡马西平均相酶免疫检测试剂的制备方法 | |
CN103739703B (zh) | 甘胆酸免疫原、抗甘胆酸特异性抗体及检测试剂 | |
CN104804079A (zh) | 伊马替尼免疫原、衍生物及合成方法、特异性抗体和检测试剂及制备方法 | |
CN104447984A (zh) | 多西紫杉醇免疫原、抗多西紫杉醇特异性抗体和多西紫杉醇检测试剂 | |
CN104530222A (zh) | 紫杉醇免疫原、抗紫杉醇特异性抗体和紫杉醇检测试剂 | |
CN106645692B (zh) | 雌三醇均相酶免疫检测试剂、制备方法及检测方法 | |
CN104788560A (zh) | 环孢霉素a免疫原、抗环孢霉素a特异性抗体和环孢霉素a检测试剂 | |
CN104569373B (zh) | 一种甲氨蝶呤均相酶免疫检测试剂及其制备和检测方法 | |
CN107353200A (zh) | 一种香草扁桃酸衍生物、其合成方法及一种香草扁桃酸免疫原、其制备方法及其应用 | |
CN105175531A (zh) | 羟脯氨酸免疫原、特异性抗体、检测试剂及其制备方法 | |
CN105131106A (zh) | 5-羟基吲哚乙酸免疫原、抗体和检测试剂及制备方法 | |
CN105092831A (zh) | 一种17-羟皮质类固醇免疫检测试剂及其制备方法 | |
CN104447745A (zh) | 一种茶碱均相酶免疫检测验试剂盒及其制备方法 | |
CN104478813A (zh) | 5-氟尿嘧啶衍生物、5-氟尿嘧啶免疫原及其抗体与5-氟尿嘧啶检测试剂盒 | |
CN104774256A (zh) | 儿茶酚胺免疫原、衍生物及合成方法、特异性抗体和检测试剂及制备方法 | |
CN102757391B (zh) | 一种苯巴比妥衍生物及其制备方法和应用 | |
CN105175530A (zh) | 一种香草扁桃酸免疫检测试剂及其制备方法 | |
CN107973836B (zh) | 醛固酮衍生物及其制备方法、醛固酮均相酶免疫检测试剂 | |
CN105131105A (zh) | 皮质醇免疫原、衍生物、抗体、检测试剂及制备方法 | |
CN103242446A (zh) | 茶碱免疫原及其制备方法和应用 | |
CN104987392A (zh) | 脱氢表雄酮免疫原、衍生物、抗体和检测试剂及制备方法 | |
CN104597238A (zh) | 一种霉酚酸均相酶免疫检测试剂及其制备和检测方法 | |
CN103804491B (zh) | 1,5-脱水山梨醇免疫原及其特异性抗体及检测试剂 | |
CN102295698B (zh) | 环孢霉素a免疫原、特异性抗体、检测试剂及检测试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210305 Address after: Room 302, 3 / F, building A5, phase II, Changsha E center, No.18 Xiangtai Road, Liuyang economic and Technological Development Zone, Changsha City, Hunan Province, 410300 Patentee after: Hunan Suyang Medical Technology Co.,Ltd. Address before: 215163 Kam Peak Road, Suzhou high tech Zone, Suzhou, Jiangsu Patentee before: SUZHOU EVERMED MEDICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: Room 302, 3 / F, building A5, phase II, Changsha E center, No.18 Xiangtai Road, Liuyang economic and Technological Development Zone, Changsha City, Hunan Province, 410300 Patentee after: Changsha Boyuan Medical Technology Co.,Ltd. Address before: Room 302, 3 / F, building A5, phase II, Changsha E center, No.18 Xiangtai Road, Liuyang economic and Technological Development Zone, Changsha City, Hunan Province, 410300 Patentee before: Hunan Suyang Medical Technology Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |